Back to Journals » Drug Design, Development and Therapy » Volume 13

Brigatinib for ALK-positive metastatic non-small-cell lung cancer: design, development and place in therapy

Total article views   Abstract views HTML views PDF downloads Totals
7,653 Dovepress* 4,207 731+ 1,275 4,938
PubMed Central* 0 2,715 598 2,715
Totals 4,207 3,446 1,873 7,653
*Since 8 February 2019
+Since July 2016

View citations on PubMed Central and Google Scholar